PPM FINAL EXAM UPDATED QUESTIONS AND ANSWERS
diabetes prevalence in US - CORRECT ANSWER✅✅✅11.6%
modifiable risk factor of diabetes - CORRECT ANSWER✅✅✅obesity (contributes to half of new
diabetes cases)
what BMI is considered obese - CORRECT ANSWER✅✅✅over 30
Who are GLP1 indicated for - CORRECT ANSWER✅✅✅T2DM + CVD risk
T2DM + CKD
goals of GLP1 s in T2DM - CORRECT ANSWER✅✅✅weight management
glycemic control
GLP1 - CORRECT ANSWER✅✅✅glucagon like peptide -1 receptor agonist
Where is GLP1 expressed - CORRECT ANSWER✅✅✅brain -> increase satiety
pancreas -> increase insulin secretion
GI tract -> slows motility
When was the first GLP1 launched - CORRECT ANSWER✅✅✅2004
When was the first generic GLP1 launched - CORRECT ANSWER✅✅✅2024 (liraglutide)
Expanding indications of GLP1s - CORRECT ANSWER✅✅✅heart failure
obstructive sleep apnea
CKD
,approved GLP1s for T2DM - CORRECT ANSWER✅✅✅Byetta
Victoza
Bydureon
trulicity
Adlyxin
Ozempic
Rybelsus
Mounjaro
approved GLP1s for weight loss - CORRECT ANSWER✅✅✅Saxenda
Wegovy
Zepound
GLP1 weight loss pipeline - CORRECT ANSWER✅✅✅new GLP1 combinations are being studied for
even more weight loss (beyond 5-15% weight loss)
When did GLP 1 prescriptions spike - CORRECT ANSWER✅✅✅2023
What lead to GLP1 popularity - CORRECT ANSWER✅✅✅social media
ease of use
Market events of GLP1 popularity - CORRECT ANSWER✅✅✅shortages
fraud waste and abuse
compounding pharmacies
off label use
cosmetic offices
direct to consumer offering
clinical vendors offering weight loss solutions
,trends in GLP1s - CORRECT ANSWER✅✅✅-weight loss GLP1 products priced at premium compared
to diabetes GLP1s
-discrepancy in access and utilization of GLP1s for weight loss
-impact on retail and food
benefit exclusions - CORRECT ANSWER✅✅✅certain categories that are not medically necessary that
employer groups can choose to provide coverage for their employees
examples of benefit exclusions - CORRECT ANSWER✅✅✅sexual dysfunction
weight loss
alopecia
cosmetic
What % of corporate plans currently cover GLP1s for weight loss - CORRECT ANSWER✅✅✅34%
medicare coverage of GLPs - CORRECT ANSWER✅✅✅only covered for diabetes and CV disease (has
option to cover but wont)
medicaid coverage of GLP1s - CORRECT ANSWER✅✅✅up to each state on how and who is covered
by GLP1s
clinical management fo GLP1s - CORRECT ANSWER✅✅✅proactive prior authorization across all
segments
electronic edit to ensure diabetes diagnosis
maximized rebates and price protection
retrospective claims auditing to mitigate FWA
lifestyle management programs
clinical evaluation of efficacy, safety and pipeline at P&T
, smart edit for GLP1s - CORRECT ANSWER✅✅✅at point of sale, diabetes diagnosis and prior therapy
use is checked and then sale can go through
"negative PA" - CORRECT ANSWER✅✅✅reverse PA if FWA is seen
clinical concerns of GLP1s - CORRECT ANSWER✅✅✅GI side effects
pulmonary aspiration
diabetic retinopathy
loss of muscle mass
increased risk of suicidality
compounded GLP-1
compounded GLP-1 risk - CORRECT ANSWER✅✅✅accidental increased concentration
pulmonary aspiration FDA update on GLP1s - CORRECT ANSWER✅✅✅label need to add pulmonary
respiration during anesthesia or deep sedation
trends in GLP1 treatment persistence - CORRECT ANSWER✅✅✅less than have use for more than 3
months
those prescribed by specialists used for longer
younger adults less likely to continue
future of GLPs - CORRECT ANSWER✅✅✅shift from focus on management to prevention
GLP1 pipeline expansion
long term safety and benefit
behavioral health definition - CORRECT ANSWER✅✅✅mental health + substance use disorders
how to phrase someone having mental illness - CORRECT ANSWER✅✅✅living with a mental illness
diabetes prevalence in US - CORRECT ANSWER✅✅✅11.6%
modifiable risk factor of diabetes - CORRECT ANSWER✅✅✅obesity (contributes to half of new
diabetes cases)
what BMI is considered obese - CORRECT ANSWER✅✅✅over 30
Who are GLP1 indicated for - CORRECT ANSWER✅✅✅T2DM + CVD risk
T2DM + CKD
goals of GLP1 s in T2DM - CORRECT ANSWER✅✅✅weight management
glycemic control
GLP1 - CORRECT ANSWER✅✅✅glucagon like peptide -1 receptor agonist
Where is GLP1 expressed - CORRECT ANSWER✅✅✅brain -> increase satiety
pancreas -> increase insulin secretion
GI tract -> slows motility
When was the first GLP1 launched - CORRECT ANSWER✅✅✅2004
When was the first generic GLP1 launched - CORRECT ANSWER✅✅✅2024 (liraglutide)
Expanding indications of GLP1s - CORRECT ANSWER✅✅✅heart failure
obstructive sleep apnea
CKD
,approved GLP1s for T2DM - CORRECT ANSWER✅✅✅Byetta
Victoza
Bydureon
trulicity
Adlyxin
Ozempic
Rybelsus
Mounjaro
approved GLP1s for weight loss - CORRECT ANSWER✅✅✅Saxenda
Wegovy
Zepound
GLP1 weight loss pipeline - CORRECT ANSWER✅✅✅new GLP1 combinations are being studied for
even more weight loss (beyond 5-15% weight loss)
When did GLP 1 prescriptions spike - CORRECT ANSWER✅✅✅2023
What lead to GLP1 popularity - CORRECT ANSWER✅✅✅social media
ease of use
Market events of GLP1 popularity - CORRECT ANSWER✅✅✅shortages
fraud waste and abuse
compounding pharmacies
off label use
cosmetic offices
direct to consumer offering
clinical vendors offering weight loss solutions
,trends in GLP1s - CORRECT ANSWER✅✅✅-weight loss GLP1 products priced at premium compared
to diabetes GLP1s
-discrepancy in access and utilization of GLP1s for weight loss
-impact on retail and food
benefit exclusions - CORRECT ANSWER✅✅✅certain categories that are not medically necessary that
employer groups can choose to provide coverage for their employees
examples of benefit exclusions - CORRECT ANSWER✅✅✅sexual dysfunction
weight loss
alopecia
cosmetic
What % of corporate plans currently cover GLP1s for weight loss - CORRECT ANSWER✅✅✅34%
medicare coverage of GLPs - CORRECT ANSWER✅✅✅only covered for diabetes and CV disease (has
option to cover but wont)
medicaid coverage of GLP1s - CORRECT ANSWER✅✅✅up to each state on how and who is covered
by GLP1s
clinical management fo GLP1s - CORRECT ANSWER✅✅✅proactive prior authorization across all
segments
electronic edit to ensure diabetes diagnosis
maximized rebates and price protection
retrospective claims auditing to mitigate FWA
lifestyle management programs
clinical evaluation of efficacy, safety and pipeline at P&T
, smart edit for GLP1s - CORRECT ANSWER✅✅✅at point of sale, diabetes diagnosis and prior therapy
use is checked and then sale can go through
"negative PA" - CORRECT ANSWER✅✅✅reverse PA if FWA is seen
clinical concerns of GLP1s - CORRECT ANSWER✅✅✅GI side effects
pulmonary aspiration
diabetic retinopathy
loss of muscle mass
increased risk of suicidality
compounded GLP-1
compounded GLP-1 risk - CORRECT ANSWER✅✅✅accidental increased concentration
pulmonary aspiration FDA update on GLP1s - CORRECT ANSWER✅✅✅label need to add pulmonary
respiration during anesthesia or deep sedation
trends in GLP1 treatment persistence - CORRECT ANSWER✅✅✅less than have use for more than 3
months
those prescribed by specialists used for longer
younger adults less likely to continue
future of GLPs - CORRECT ANSWER✅✅✅shift from focus on management to prevention
GLP1 pipeline expansion
long term safety and benefit
behavioral health definition - CORRECT ANSWER✅✅✅mental health + substance use disorders
how to phrase someone having mental illness - CORRECT ANSWER✅✅✅living with a mental illness
